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ABSTRACT
Introduction  Although hormonal-therapy is the preferred first-line treatment for 
hormone-responsive, HER2 negative metastatic breast cancer, no data from clinical 
trials support the choice between hormonal-therapy and chemotherapy. 
Methods Patients were divided into two groups according to the treatment: 
chemotherapy or hormonal-therapy. Outcomes in terms of clinical benefit and median 
overall survival (OS) were retrospectively evaluated in the two groups. To calculate 
the time spent in chemotherapy with respect to OS in the two groups, the proportion 
of patients in chemotherapy relative to those present in either group was computed 
at every day from the start of therapy.
Results From 1999 to 2013, 119 patients received first-line hormonal-therapy 
(HT-first group) and 100 first-line chemotherapy (CT-first group). Patients in the CT-
first group were younger and with poorer prognostic factors as compared to those 
in HT-first group. Clinical benefit (77 vs 81%) and median OS (50.7 vs 51.1 months) 
were similar in the two groups. Time spent in chemotherapy was significantly longer 
during the first 3 years in CT-first group (54-34%) as compared to the HT-first group 
(11-18%). This difference decreased after the third year and overall was 28% in the 
CT-first group and 18% in the HT-first group. 
Conclusions The sequence first-line chemotherapy followed by hormonal-therapy, 
as compared with the opposite sequence, is associated with a longer time of OS spent 
in chemotherapy. However, despite the poorer prognostic factors, patients in the CT-
first group had a superimposable OS than those in the HT-first group.
INTRODUCTION
Breast cancer is not a single disease and it is now 
accepted that there are at least four different biological 
subtypes which comprise endocrine responsive disease 
divided in Luminal A (estrogen receptor [ER] and/or 
progesterone receptor [PgR] positive (+), HER2 negative 
(-), low proliferating activity) and Luminal B (ER and/or 
PgR+, HER2-, high proliferating activity), HER2+ disease 
(HER2+ regardless of hormone receptor status) and triple-
negative disease (ER, PgR and HER2 negative [1-3]. 
The absolute majority of all newly diagnosed breast 
cancer patients (about 60-65%) [4] has hormone receptor 
positive (HR+) tumors; despite the best prognosis, still 
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many patients relapse after treatment, forming the most 
common subtype of metastatic breast cancer (MBC) 
patients [5].
With current treatments, the median overall survival 
of HR+ MBC patients is estimated to be greater than 50 
months [6] and it is crucial to plan the best sequence of 
treatments as it is expected that these patients receive 
multiple lines of therapy.
Most of HR+ MBC patients are treated with both 
hormonal therapy (HT) and chemotherapy (CT) during the 
course of their disease. 
International guidelines indicate that HT is the 
preferred first-line treatment option for these patients 
[7-10] restricting the use of CT only to patients not 
responsive to HT or at risk of visceral crisis. However, 
this indication derives mostly from expert opinions and 
from very few randomized controlled trials. 
A systematic review of trials comparing HT with 
CT as first-line treatment of MBC showed no significant 
difference in overall survival (OS) between the two types 
of treatment and an increased toxicity associated with 
CT [11]. However, no modern drugs, such as aromatase 
inhibitors or taxanes, were used in these trials and patients 
included in the CT arms did not receive maintenance HT 
after CT, which is now currently administered, although 
without a strong level of evidence [12]. 
Therefore, there are no strong data supporting that 
delivering first HT and CT thereafter provides a better 
outcome in terms of OS as compared to the reverse 
sequence. 
The aim of the present study is to retrospectively 
compare the two treatment sequences in terms of 
objective response rate (ORR), clinical benefit rate (CBR), 
progression-free survival (PFS), OS, CT duration and time 
spent in CT (related to OS) in HR+/HER2- MBC patients.
MATERIALS AND METHODS
All consecutive MBC patients treated with a 
first-line therapy (CT or HT with or without biological 
therapy) from 1999 to 2013 were included in this 
monocentric retrospective observational study. Patients 
were classified in four subgroups according to the 
biological characteristics of their primary tumor: Luminal 
A (ER and/or PgR+, HER2- and Ki67 < 20%), Luminal 
B (ER and/or PgR+, HER2- and Ki67 ≥ 20%), HER+ 
(immunohistochemistry score of 3+ or fluorescence in situ 
hybridization amplified regardless of hormonal status), 
and Triple-Negative (ER and PgR and HER2 negative) 
[13].
For the present study, we selected only Luminal A 
and B patients treated with at least one line of HT or one 
line of CT. Eligible patients were divided into two groups: 
the HT-first group including patients receiving HT as first-
line treatment and the CT-first group including patients 
receiving CT as first-line treatment.
The choice between first-line HT or CT was 
performed by the treating physician on the basis of 
patients’ and disease characteristics. 
Patients’ characteristics, histological and biological 
data from primary tumor, treatment history with clinical 
response at each line of treatment, PFS and survival data 
were collected. 
Statistical analysis
Patient and disease characteristics were analyzed 
using descriptive statistics. For each prognostic factor, 
heterogeneity between the two study groups was estimated 
by the Pearson Chi-square test or the Mann-Withney test.
Clinical response to therapy was assessed at the 
end of the first-line of treatment by clinical examination 
and imaging procedures, and classified according to 
RECIST guidance [14] . Objective response was defined 
as complete response (CR) if there was no evidence of 
residual tumor at the metastasis (MTS) site(s), partial 
response (PR) if the MTS mass was reduced by at least 
50%. An increase in MTS size by 25% (as compared 
to baseline measurement) or new MTS appearance was 
considered as disease progression (PD). If the criteria 
for objective response or progression were not met, the 
disease was considered as stable (SD). Patients who 
experienced CR, PR or SD were considered as having 
obtained a CB from the therapy.
 OS was estimated from the date of MTS diagnosis 
to the date of last contact or death from any cause. 
Distant disease-free survival (DDFS) was estimated 
from the date of diagnosis of the primary tumor and the 
date of MTS diagnosis.
PFS was estimated from the date of first-line MBC 
therapy to the date of first subsequent PD.
Survival curves were obtained using the Kaplan-
Meier method and differences between treatment 
sequences were assessed by the log-rank test [15]. 
Cox regression models were used for multivariate 
analysis to assess the independent role of each prognostic 
factor with respect to OS, while adjusting for the effects 
of the other factors. The variables included in the model 
as covariates were patient age at the time of relapse, 
menopausal status, tumor stage at diagnosis, sequence of 
systemic treatment (HT-first vs CT-first), median DDFS, 
presence of de novo metastatic disease, number of MTS 
sites, presence of visceral MTS (liver, lung and/or brain), 
presence of non-visceral MTS (bone, lymph node, skin 
and/or others). The multivariate analyses started from 
the full model, with all covariates included. Factors not 
significantly associated with survival were removed from 
the model by means of a step-down procedure based on 
the likelihood ratio test. 
In subgroup analyses, effects of the CT-first 
sequence as compared to the HT-first sequence across the 
strata of each covariate were assessed by introducing the 
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appropriate interaction terms in the Cox model. These 
covariates by treatment interaction terms were introduced 
in the model one at a time. The likelihood ratio test 
was used to evaluate the statistical significance of each 
interaction term. 
Logistic regressions were used to predict a 
relationship between the use of CT as first-line treatment 
and the following factors: patient age at the time of 
MTS diagnosis, menopausal status, presence of de novo 
metastatic disease, number of MTS sites and type of MTS 
Table 1: Patient and disease  characteristics  by treatment group
HT-first group (%) CT-first group (%) p¶ 
Total number of patients 119 (54) 100 (46)
Median age – year (range)
At primary tumor diagnosis
At metastasis diagnosis
61 (33-93)
67 (37-93)
54 (32-82)
57 (32-85)
0.049
<0.001
Menopausal status 
Premenopausal
Postmenopausal
31 (26)
88 (74)
45 (45)
55 (55)
0.003
Stage at diagnosis 
I
II
III
missing
19 (19)
35 (35)
44 (44)
2  (2)
14 (22)
17 (27)
32 (51)
-
0.454
De novo metastatic disease (stage IV) 
            Yes
            No
19  (16)
100  (84)
37  (37)
63  (63) 0.001
Adjuvant/Neoadjuvant CT# 
Anthracycline alone / or + other
Taxane alone / or + other
Anthracycline and taxane  alone / or+ other
Other
None
 4 (4)
19 (19)
21 (21)
25 (25)
31 (31)
-
31 (49)
14 (22)
18 (29)
-
<0.001
Adjuvant/Neoadjuvant HT# 
Only Tamoxifen 
Aromatase Inhibitors 
Tamoxifen →Aromatase Inhibitors
None
Missing
49 (49)
26 (26)
12 (12)
12 (12)
-
28 (45)
14 (23)
10 (15)
 10 (15)
1 (2)
0.570
Disease-free survival #, months 
            ≤12
            >12 – 36
            >36
 6  (6)
28  (29)
64  (65)
              2  (3)
16  (25)
45  (72)
0.599
Number of metastatic sites 
1
2
≥ 3
76 (64)
24 (20)
19 (16)
45 (45)
23 (23)
32 (32)
0.008
Sites of metastasis 
Liver – yes
             no
Lung – yes
             No
Liver and Lung – yes
                             No
Brain – yes
             no
Bone – yes
             no
Lymph node – yes
                         no
14 (12)
105  (88)
15 (13)
104  (87)
3 (2)
116 (98)
1 (1)
118  (99)
79 (67)
40  (33)
46 (39)
73  (61)
35 (35)
65  (65)
25 (25)
75  (75)
7 (7)
93  (93)
3 (3)
97  (97)
60 (60)
40  (40)
41 (41)
59  (59)
<0.001
<0.001
0.114
0.234
0.328
0.724
¶P values: from Pearson Chi-square test for categorical variables; from Mann-Withney test for continuous variable (age); 
#Metastatic ab initio excluded; Abbreviations: HT: hormonal-therapy; CT: chemotherapy
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(visceral versus non-visceral). All statistical analyses were 
two-sided and were carried out using the SPSS package 
(version 18.0 for Windows). Significance was accepted for 
P values < 0.05.
With the aim of calculating the time spent in 
CT with respect to OS in the two patients groups, the 
proportion of patients in CT relative to those present in 
either group was computed at every day from the start of 
therapy. To adjust for OS, the proportions of patients in CT 
were weighted using as weights the survival function of 
the two groups. The weighted proportions were summed 
along time to estimate the cumulative average proportion 
of time patients spent in CT until then. For each proportion 
the 95% confidence intervals, based on the binomial 
distribution, were computed. LOWESS smoothing method 
has been applied to highlight the trend of proportions [16].
RESULTS
Three hundred twenty-nine patients with MBC were 
identified and 219 were included for this analysis 
(Figure 1). Of the 110 patients who were excluded 
60 were HER2+, 37 were triple-negative, 4 patients 
received CT concomitantly with HT as first-line treatment, 
4 patients had a second non-breast tumor before the 
diagnosis of MTS and 2 patients did not receive any 
systemic therapy for their disease.
One hundred nineteen patients (54%) with hormone-
responsive HER2- MBC received HT as first-line 
treatment with or without following CT (HT-first group) 
while 100 (46%) patients were treated with a first-line CT 
with or without following HT (CT-first group). 
Table 1 summarizes patients and disease 
characteristics.
Median age at MTS diagnosis was 64 years (range 
32-93); patients in the CT-first group were younger 
(median age 57 versus 67 years, p < 0.001) and more 
frequently in pre-menopausal status (45% versus 26%, p 
= 0.003) as compared to patients in the HT-first group.
Patients in the CT-first group were initially 
diagnosed at a more advanced stage as compared to 
patients in the HT-first group (37% versus 16% in stage 
IV, p = 0.0014) but DDFS between the primary tumor and 
the appearance of MTS was similar in the two treatment 
groups (p = 0.599). As expected, patients in the CT-first 
group had more metastatic sites (≥3 in 32% versus 16%, 
p = 0.008) and a greater liver or lung involvement than 
patients in the HT-first group (35% and 25% versus12% 
and 13%, respectively, p < 0.001). Nevertheless, the 
occurrence of concomitant liver and lung metastases was 
Figure 1: Flow-chart for the selection of the patient population to be included in the study.
Oncotarget44804www.impactjournals.com/oncotarget
similarly low in the two treatment groups (2% and 7%, p 
= 0.114).
 Considering only patients with stage I to III primary 
tumors, delivery of neo/adjuvant chemotherapy regimen 
differed between the two groups (p < 0.001): in particular, 
taxane alone or in combination with other drugs were 
delivered more often in the CT-first group than in the HT-
first group (49% versus 19%). All patients in the CT-first 
group underwent at least one type of CT regimen while 
about one third (31%) of patients in the HT-first group did 
not receive any.
Neo/adjuvant hormonal therapy was given to a 
similar proportion of patients in the two treatment groups.
At the time of this analysis, in the HT-first group 
42 patients (35%) did not have yet received any CT and, 
conversely, in the CT-first group 23 patients (23%) did not 
have yet receive any HT (Table 2).
The median numbers of lines of treatments (HT 
plus CT) was similar in the two groups: 4 (range 1-10) 
in HT-first group and 3 (range 1-11) in CT-first group. 
No significant difference in the total duration of HT was 
observed between the two groups (median duration: 20.7 
and 19.3 months in the HT-first and CT-first groups, 
respectively, p = 0.692). The total CT duration was similar 
in the two treatment groups (11.3 and 8.3 months in the 
HT-first and CT-first groups, respectively, p = 0.318).
A maintenance HT after first-line CT was 
administered in 63 patients (63%) in the CT-first group 
and letrozole was the most widely used drug (about 52% 
of patients).
Patients in the CT-first group received more 
frequently a poly-CT as first-line CT than patients in HT-
first group (56% versus 22%). Among those patients in 
the CT-first group who received poly-CT, about one third 
Table 2: MBC therapy characteristics by treatment group
HT-first group (%) CT-first group (%) p¶ 
Median number of HT lines (range) 2  (1-5) 1 (0-5) <0.001
Total number of HT lines 
0
1
2
3
>3
0  (0)
119 (100)
80 (67)
48 (40)
 33 (28)
23  (23)
77  (77)
45  (45)
24  (24)
11  (11)
Median total HT duration, months (range) 20.7 (1.8-200.7) 19.3 (0.5-116.8) 0.692
Median number of CT lines (range) 1 (0-6) 2 (1-7) <0.001
Total number of CT lines 
0
1
2
3
4
> 4
42  (35)
77  (68)
56  (47)
35  (29)
13  (11)
18  (15)
0  (0)
100 (100)
56  (56)
36  (36)
24  (24)
17  (17)
Median total CT duration, months (range) 11.3 (0.2-38.2) 8.3 (0.03-53.2) 0.318
First line chemotherapy 
Polychemotherapy
Monochemotherapy
None
Missing
26 (22)
51 (43)
42 (35)
0  (0)
56 (56)
43 (43)
0  (0)
1 (1)
0.004
Type of CT at first line
Anthracycline alone
Taxane alone
Anthracycline and taxane
Taxane and other
Other
 No CT
2  (2)
12  (10)
9 (8)
12  (10)
42  (35)
42  (35)
9  (9)
16  (16)
27  (27)
19  (19)
29  (29)
0  (0)
0.004
Type of HT at first line
Tamoxifen
Non-steroidal aromatase inhibitor
Steroidal aromatase inhibitor
Fulvestrant
Everolimus
Other 
No HT
11  (9)
57  (48)
19  (16)
27  (23)
1  (1)
4  (3)
0  (0)
13  (13)
43  (43)
9  (9)
11  (11)
1  (1)
0  (0)
23  (23)
<0.001
¶P values: from Pearson Chi-square test for categorical variables; from Mann-Withney test for continuous variable; 
Abbreviations: HT: hormonal-therapy; CT: chemotherapy
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(18 out of 56) had de novo metastatic disease. Poly-CT 
consisted of the combination of an anthracycline and a 
taxane more often in the CT-first group than in the HT-
first group (27% versus 8%).
The most commonly drug used as first-line HT was a 
non-steroidal aromatase inhibitor (letrozole or anastrozole) 
in both groups (48% versus 43%) while fulvestrant was 
more frequently used as first-line HT in the HT-first group 
as compared to the CT-first group (23% versus 11%). 
Only 2 patients (1 in HT-first group and 1 in CT-
first group) received everolimus in association with 
exemestane. 
Table 3: Prognostic factors associated with a preferential use of CT as first-line treatment of MBC
Prognostic  factor Univariate Multivariate
OR 95% CI p OR 95% CI p
Age
≤65 years
>65 years
1 (ref)
0.33
-
0.21-0.53
<0.001 1 (ref)
0.29
-
0.17-0.49
<0.001
Menopausal status
premenopause
postmenopause
1 (ref)
0.40
-
0.24-0.66
0.004 rfm*
-
-
-
0.102
De novo metastatic disease
no
yes
1 (ref)
2.92
-
1.64-5.17
<0.001 1 (ref)
2.89
-
1.54-5.44
0.001
Number of metastatic sites
1
2
≥3
1 (ref)
2.05
2.91
-
1.17-3.57
1.59-5.34
0.001 rfm-
-
-
-
-
0.400
Metastasis type
non-visceral
visceral
1 (ref)
5.15
-
3.09-8.57
<0.001 1 (ref)
5.80
-
3.34-10.06
<0.001
DDFS
≤median of 36.3 months
>median of 36.3 months
1 (ref)
0.48
-
0.30-0.76
0.002 rfm --
0.412
Abbreviations: *rfm, removed from the final model
Figure 2: Kaplan-Meier curves or overall survival according to treatment sequence.
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Objective response and clinical benefit
The ORR (CR or PR) observed after the first-
line HT was not statistically different between the two 
sequence groups (19.8% and 30.6% in the HT-first group 
and in the CT-first group, respectively, p = 0.094). A 
similar result was observed when considering the first-line 
of CT (27.5% and 38.9% in the HT-first and the CT-first 
groups, respectively, p = 0.134).
No significant differences between the two treatment 
groups were observed in terms of CBR either after the 
first-line of HT (75.9% versus 79.2%, p = 0.6) nor the 
first-line of CT (73.9% versus 83.3%, p = 0.147).
PFS and overall survival
Median follow-up was 3.14 years (range 0.12-16.70) 
and was similar for the two groups (3.31 years for the 
HT-first group and 2.89 years for the CT-first group, p = 
0.246).
PFS after the first-line treatment was comparable in 
the two groups, being 13.4 months (range 2.3-74.4) for the 
HT-first group and 13.9 months (range 1.6-114.0) for the 
CT-first group (p = 0.911).
Overall, 109 deaths were recorded: 62 in the HT-first 
group and 47 in the CT-first group. Median OS was 50.7 
months (95%CI 35.2-66.3) and 51.1 months (95%CI 42.5-
59.6) for the HT-first and the CT-first groups, respectively 
(p = 0.548, Figure 2). In the HT-first group, the percentage 
of surviving patients at 1, 2, 3, 4, and 5 years was 95.8%, 
86.1%, 76.5%, 53.9% and 45.5% respectively. The 
percentages observed in the CT-first group at the same 
time intervals were 89.5%, 77.4%, 66.7%, 55.7% and 
42.1%. 
Time spent in CT
Figure 3 shows the estimates of the proportion of 
time/patients spent in CT during the follow-up. Data are 
truncated at the eighth year from starting therapy because 
beyond this time the small number of patients prevents 
to achieve reliable findings. At the beginning of therapy, 
the proportion of patients in CT in the CT-first group was 
much higher than in the HT-first group: indeed at the first 
year the estimates were 0.54 (95% CI 0.46-0.60) and 
0.11 (95% CI 0.0-0.18), respectively. Over time, these 
proportions became closer: 0.34 (95% CI 0.26-0.44) in 
CT-first group and 0.18 (95% CI 0.11-0.27) in HT-first 
group within three years and 0.28 (95% CI 0.17-0.45) and 
0.18 (95% CI 0.09-0.31) respectively at the end of the 
investigated period. 
Univariate, multivariate and subgroup analyses
In univariate analyses, the presence of visceral 
(liver, lung and/or brain) MTS and patients age were 
Figure 3: Time spent in CT (chemotherapy) related to OS (overall survival) in HT (hormonal-first group and in CT-
first group. CT-first group solid line; HT-first group dashed line; 95%CI dot lines.
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significantly associated with OS (p = 0.011 and 0.047, 
respectively). In multivariate analyses, only the presence 
of visceral MTS was a significant independent predictor of 
survival (HR = 1.6, 95%CI 1.1-2.4, p = 0.022).
Subgroup analyses of OS comparing the CT-first 
group versus the HT-first group within the strata of each 
prognostic factors indicated a possible interaction between 
treatment sequence and patient age; the significant higher 
HR of death in patients aged more than 65 years (1.47 
versus 0.68, p = 0.45) indicates that the HT-first sequence 
might be more effective in older patients in terms of 
OS (Figure 4). Conversely, no significant evidence of 
interaction was observed between the type of treatment 
sequence and menopausal status, presence of de novo 
metastatic disease, number of MTS sites, DDFS or 
presence of visceral or non-visceral MTS. Nevertheless, 
the HT-first sequence appeared favored in subgroups of 
patients at lower risk, that is in postmenopausal status, 
presenting a less aggressive disease (longer DDFS), with 
single non-visceral MTS.
Prediction of the use of CT as first-line treatment 
of MBC
In univariate logistic regressions, the presence of 
de novo metastatic disease (OR = 2.92, p < 0.001), the 
presence of 2 or ≥3 sites of MTS (OR = 2.05 and 2.91 
Figure 4: Forest plot of subgroup analyses of overall survival comparing the CT-first sequence versus the HT-first 
sequence within the strata of each prognostic factor. ¶overall comparison of CT-first sequence versus HT-first sequence adjusted 
for all prognostic factors.
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respectively, p = 0.001) and the type of MTS (visceral 
versus non-visceral, OR = 5.15, p < 0.001) were significant 
predictors of the use of CT as first-line treatment of MBC. 
On the contrary, older age (>65 years, OR = 0.33, p < 
0.001), postmenopausal status (OR = 0.40, p = 0.001) 
and long DDFS (OR = 0.48, p = 0.0002) were significant 
predictors of the non-use of CT as first-line therapy (Table 
3).
In multivariate regressions, de novo metastatic 
disease and MTS type were significant independent 
predictors of the preferential use of CT as first-line 
treatment (p = 0.001 and p < 0.001, respectively) while 
patient age was significantly associated with the preferred 
non-use of CT (p < 0.001). By contrast menopausal status, 
a high number of MTS sites and a long DDFS were 
excluded from the final model (p = 0.102, 0.400 and 0.412, 
respectively).
DISCUSSION
In our retrospective observational study, we 
observed that HR+/HER2- MBC patients treated with 
the sequence, first-line CT followed by HT, as compared 
with the reverse sequence, despite the poorer prognostic 
factors, showed a similar median OS of about 51 months. 
In the first three years, this result was obtained at the price 
of a longer of OS spent in CT for patients starting with CT 
as compared to patients treated with a first-line HT but this 
difference decreased after the third year and overall was 
28% in CT-first group and 18% in HT-first group. Type 
of metastatic disease (visceral versus non-visceral) and 
younger age are strong predictors of the use of a first-line 
CT; the presence of visceral metastases is an independent 
adverse prognostic factor in HR+/HER2- MBC patients.
Our results are consistent with data of the literature 
showing that younger age and visceral metastases as 
adverse prognostic factors in HR+/HER2- MBC patients 
[17-19] and partially support current guidelines that 
indicate the presence of visceral metastases, although 
symptomatic, as the main criterion for choosing CT as 
first-line treatment of these patients [8-10].
Our study supports the results of older randomized 
trials [11] that showed no differences in terms of efficacy 
between HT and CT as first-line treatment of HR+ MBC 
patients. However, the absence of randomization allowed 
to treat patients at worse prognosis with CT obtaining the 
same results in terms of survival of the patients with a 
better prognosis treated with HT. Taking into account the 
median survival of about 4 years in patients with adverse 
prognostic factors, the beneficial effect of CT used as 
first-line treatment in this subgroup of patients cannot be 
excluded.
Our data are in line with those of a recent study 
showing that, in real life, a high percentage of patients 
with HR+ disease receive initial CT in contrast with the 
recommendation of the current available guidelines [20]. 
Of note, the overall survival of patients treated with 
first-line CT in the study by Lobbezoo et al was worse 
(about 16 months) than the one of our patients ( about 
51 months). This difference can be largely explained by 
the different patients’ characteristics and pattern of cares 
in two studies (e.g. more bone disease and less multiple 
metastatic sites in our patients).
One recent observational study comparing CT 
versus HT as first-line treatment obtained our own results 
in terms of overall survival (37.5 months and 33.4 months 
respectively, log-rank test, P = 0.62) and progression-free 
survival (13.3 months and 9.9 months respectively, log-
rank test, P = 0.92) [21].
Another observational study showed that HR+ 
MBC patients receive a median of 3 lines of CT with 
approximately 40% of patients treated with fourth-line 
CT [22]. Our study confirmed that these patients received 
a median of 4 (HT-first group) or 3 (CT-first group) lines 
of treatment for their disease and median durations of HT 
and CT were the same in the two groups. However, to our 
knowledge, this is the first study showing that patients 
treated with CT as first-line treatment spend more time of 
their survival in CT as compared to patients starting with 
HT with a potential negative impact on their lives.
The main limitation of our study is its retrospective 
nature. This factor can lead to several bias including 
selection of patients and the choice of the treatment. On 
the other hand, no randomized trial of HT versus CT 
with treatments including currently used drugs, such as 
aromatase inhibitors, fulvestrant or taxanes, are available. 
Patients included in this study were treated with 
modern HT and CT but they did not receive the most 
recently drugs everolimus (used only in two patients) or 
cyclin-dependent kinase 4/6 inhibitors (palbociclib or 
ribociclib). The improvements in efficacy obtained in 
randomized trials from the combination of everolimus and 
exemestane [23] or palbociclib with letrozole [24] or with 
fulvestrant [25], or ribociclib plus letrozole [26] could lead 
in the future to better outcomes with HT and with less use 
of CT in HR+/HER2- MBC patients.
Moreover, another important limitation is that 
our study does not answer the question whether HT in 
maintenance should be given.
In conclusion, our study suggests that HR+/HER2- 
MBC patients treated with first-line CT followed by HT, 
despite the poor prognostic factors, had clinical outcomes 
similar to those of patients treated with the reverse 
sequence. However, these results are obtained at the price 
of a longer time of OS spent in CT.
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